BioCentury | Jun 7, 2012
Distillery Techniques

Technology: Drug platforms

...drug-related autoimmune reactions that could aid the design of safer therapeutics. In cells expressing the HLA-B 5701...
BioCentury | Jun 7, 2012
Tools & Techniques

HLA in sequence

...lymphocytes. Autoimmune adverse drug reactions-such as abacavir hypersensitivity syndrome in patients expressing the major histocompatibility complex class I B 5701 ( HLA-B 5701...
...and the Cardiff University School of Medicine . In cultured antigen-presenting cells, abacavir altered the HLA-B 5701...
...isolated T cell lines from healthy HLA-B 5701 donors, culture with abacavir plus peptides that bound HLA-B 5701...
BioCentury | Jan 2, 2012
Company News

Roche sales and marketing update

Roche launched the Roche HLA-B*5701 Screening Test in Europe to identify patients with the HLA-B*5701 allele, which is associated with a higher risk for hypersensitivity to HIV drug abacavir. The test runs on the Cobas...
BioCentury | Nov 1, 2010
Company News

Linkage Biosciences sales and marketing update

Linkage Biosciences launched three human leukocyte antigen (HLA) typing tests in the U.S. The intermediate resolution HLA-DQ test types the major histocompatibility complex class II DQ locus alpha 1 ( HLA-DQA1 ) and major histocompatibility complex class...
BioCentury | Oct 1, 2010
Clinical News

Adverse event consortium begins second phase

...year, the consortium published data from the study's first phase that showed patients carrying the HLA-B 5701...
BioCentury | Aug 16, 2010

PBMs become companions

...sensitivity to warfarin Ziagen abacavir from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Major histocompatibility complex class I B 5701(HLA-B 5701) HIV patients carrying the HLA-B 5701...
...Tykerb Ziagen abacavir from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) Major histocompatibility complex class I B 5701 (HLA-B 5701) HIV patients carrying at least one HLA-B 5701...
BioCentury | May 31, 2010
Company News

Medco Health Solutions Inc. sales and marketing update

Pharmacy benefit manager Medco's Precision Health Solutions business unit will launch a suite of pharmacogenetic services in July. The unit will offer a CYP2C19 allele test for cardiovascular drug Plavix clopidogrel; a test to identify...
BioCentury | Jun 11, 2009
Distillery Therapeutics

Indication: Hepatic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Liver failure HLA-B5701; SNP rs2395029 A genomewide association study suggests the HLA-B5701 allele could help assess risk of antibiotic-induced liver...
BioCentury | Jun 3, 2009
Clinical News

Consortium publishes liver tox markers

...of a genomewide association study that showed patients carrying at least one copy of the HLA-B 5701...
BioCentury | Mar 9, 2009
Clinical News

Ziagen abacavir regulatory update

FDA cautioned healthcare professionals against using skin patch testing to immunologically confirm suspected cases of hypersensitivity reactions in patients treated with abacavir. The agency said data from several research reports suggest that testing may miss...
Items per page:
1 - 10 of 16